| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | DIRS1; FNDC6; IL-20R2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL20RB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL20RB抗体的3篇文献示例(注：内容为模拟概括，仅供参考)：
1. **文献名称**：*Targeting IL-20RB inhibits psoriasis-like skin inflammation*
**作者**：Chen, L. et al.
**摘要**：该研究开发了靶向IL20RB的单克隆抗体，通过抑制IL-20家族细胞因子的信号传导，显著减轻小鼠银屑病模型的皮肤炎症和角质过度增生，提示其在自身免疫性疾病中的治疗潜力。
2. **文献名称**：*IL-20RB signaling promotes colorectal cancer progression*
**作者**：Wang, Y. et al.
**摘要**：研究揭示IL20RB在结肠癌中高表达，其抗体可通过阻断IL-19/IL-20介导的STAT3激活，抑制肿瘤血管生成和癌细胞迁移，为靶向IL20RB的抗癌策略提供依据。
3. **文献名称**：*Neutralizing IL20RB antibody alleviates rheumatoid arthritis via modulating Th17 response*
**作者**：Zhang, H. et al.
**摘要**：实验证明抗IL20RB抗体可减少类风湿性关节炎模型小鼠的关节炎症和骨侵蚀，机制与抑制IL-26驱动的Th17细胞分化及促炎因子分泌相关。
(注：上述文献及作者为假设性描述，实际文献需通过学术数据库检索确认。)
The interleukin-20 receptor beta (IL20RB), a subunit of the IL-20 receptor complex, is a transmembrane protein belonging to the type II cytokine receptor family. It pairs with IL20RA or IL6ST (gp130) to form functional heterodimeric receptors for cytokines IL-19. IL-20. and IL-24. which are part of the IL-10 cytokine family. These cytokines regulate immune responses, inflammation, and tissue remodeling by activating downstream JAK-STAT signaling pathways. IL20RB is expressed in epithelial tissues, immune cells, and endothelial cells, playing roles in skin homeostasis, wound healing, and pathogenic processes like psoriasis, rheumatoid arthritis, and cancer.
IL20RB-targeting antibodies are investigational tools designed to modulate IL-20-mediated signaling. In autoimmune and inflammatory diseases, excessive IL-20 cytokine activity drives hyperproliferation of keratinocytes (psoriasis) or synovial inflammation (arthritis). Blocking IL20RB with monoclonal antibodies may inhibit pro-inflammatory cytokine signaling, potentially reducing disease progression. In oncology, IL20RB overexpression in certain tumors correlates with angiogenesis and metastasis, making it a candidate for antibody-based therapies. Current research focuses on validating IL20RB's therapeutic potential through preclinical models and early-phase clinical trials, aiming to balance efficacy with minimal off-target effects. These antibodies may also serve as diagnostic biomarkers for diseases linked to dysregulated IL-20 family signaling.
×
